Get regular updates to your inbox.
It was around this time last year that some people began to envision what life might be like after the COVID-19 pandemic ended. While the first COVID-19 vaccination wasn’t officially administered until last December, talk about the jab was on the horizon last fall. That’s what prompted some to…
Read more
Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…
A Phase 1 trial assessing how cudetaxestat, an investigational treatment for idiopathic pulmonary fibrosis (IPF), interacts with two approved IPF treatments, Ofev (nintedanib) and Esbriet (pirfenidone), is now enrolling healthy volunteers, Blade Therapeutics, the therapy’s developer, announced. The trial (NCT04939467) is aiming to enroll 86 healthy adults, ages 18 to 55.
Burying her head in the sand used to be easier than openly talking about death, says columnist Christie Patient. But that’s changed.
Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.
Becoming educated and informed about PF is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your PF journey.
There is no cure for PF yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
